<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04100005</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-008</org_study_id>
    <nct_id>NCT04100005</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease</brief_title>
  <official_title>A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to correlate microbiome sequencing data with information provided by&#xD;
      patients and their medical records regarding Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Research Study is to better understand how the genetic information in&#xD;
      subject's microbiome correlates to the information provided in surveys and in medical records&#xD;
      regarding Crohn's disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Correlation of Microbiome to Crohn's Disease via Relative Abundance Found in Microbiome Sequencing</measure>
    <time_frame>1 year</time_frame>
    <description>Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized among specific gastrointestinal disease types.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of Sequencing Methods</measure>
    <time_frame>1 year</time_frame>
    <description>To validate the methods used to sequence samples</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Crohn Colitis</condition>
  <condition>Crohn's Ileocolitis</condition>
  <condition>Crohn Ileitis</condition>
  <condition>Crohn Disease of Ileum</condition>
  <condition>Crohn's Disease Relapse</condition>
  <condition>Crohn's Gastritis</condition>
  <condition>Crohns Disease Aggravated</condition>
  <condition>Crohn Disease in Remission</condition>
  <condition>Crohn's Jejunitis</condition>
  <condition>Crohn's Duodenitis</condition>
  <condition>Crohn's Disease of Pylorus</condition>
  <condition>Crohn's Esophagitis</condition>
  <condition>Crohn's</condition>
  <arm_group>
    <arm_group_label>Crohn's disease</arm_group_label>
    <description>Patients who have been diagnosed with Crohn's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>There is no intervention for this study.</description>
    <arm_group_label>Crohn's disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been diagnosed with Crohn's disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent, demonstrating that the patient understands the procedures&#xD;
             required for the study and the purpose of the study&#xD;
&#xD;
          2. Male or female patients age 12 and older. (interest is given to children 12 and older&#xD;
             to compare with mothers).&#xD;
&#xD;
          3. Diagnosis of Non-Fistulating Crohn's disease confirmed by at least one of the&#xD;
             following&#xD;
&#xD;
               1. Colonoscopy&#xD;
&#xD;
               2. Capsule Endoscopy&#xD;
&#xD;
               3. Computerized Tomography (CT) Scan&#xD;
&#xD;
               4. Magnetic Resonance Imaging (MRI)&#xD;
&#xD;
               5. Balloon-assisted enteroscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to sign informed consent form&#xD;
&#xD;
          2. Presence of Fistulating Crohn's disease&#xD;
&#xD;
          3. Treatment with antibiotics within 2 weeks prior to screening&#xD;
&#xD;
          4. Treatment with probiotics within 6 weeks prior to screening.&#xD;
&#xD;
          5. History of bariatric surgery, total colectomy with ileorectal anastomosis or&#xD;
             proctocolectomy.&#xD;
&#xD;
          6. Postoperative stoma, ostomy, or ileoanal pouch&#xD;
&#xD;
          7. Participation in any experimental drug protocol within the past 12 weeks&#xD;
&#xD;
          8. Treatment with total parenteral nutrition&#xD;
&#xD;
          9. Any clinically significant evidence of disease that could interfere with the subject's&#xD;
             ability to enter the trial&#xD;
&#xD;
         10. Inability to adequately communicate with the investigator or their respective designee&#xD;
             and/or comply with the requirements of the entire study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>8053390549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>18053390549</phone>
    <email>jordan@progenabiome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>drsabinehazan@progenabiome.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Daniels, MS</last_name>
      <phone>805-339-0549</phone>
      <email>jordan@progenabiome.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Duodenitis</mesh_term>
    <mesh_term>Ileitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Only aggregated and deidentified data will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

